Souhaitez-vous accéder aux communiqués récents ?

         PRESS RELEASE AB SCIENCE PRESENTS ITS ANNUAL FINANCIAL RESULTS AS OF 31 DECEMBER 2025 AND KEY EVENTS FOR THE PERIOD Financial and corporate position Operating loss of €3.8 million as of 31...

– Quarterly results marked by 104% revenue growth and improved operating performance – – Company issues full-year 2026 revenue guidance – – Announces Humana is now covering the TULSA Procedure™ – ...

Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Elzonris Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...

FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancerBria-BRES+ is BriaCell’s next generation...

Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presentedBiomarker analyses from the ongoing Phase 3 study evaluating predictors of response PHILADELPHIA and VANCOUVER,...

VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) a developer of marijuana and...

Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4/6 inhibitor treatments shows quality of life (QOL) largely preservedIdentification of...

Marvel Biosciences Corp. announces it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204.

— Represents Biomerica’s First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy — Canada Has One of the Highest IBS Prevalence Rates in the World — an Estimated...

OTTAWA, March 30, 2026 (GLOBE NEWSWIRE) -- Proponents of public universal health care across Canada are calling for the closure of Grifols facilities in the wake of two deaths in Winnipeg of people...